Author

Elizabeth C. Hannan

University of IowaORCID 0000-0001-7010-4233Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:perturbation response prediction· 1 Assay:proteomics· 1

Frequent Co-Authors

Adam J. DupuyiD· 2 shared Jesse D. RiordaniD· 2 shared Rebekah M. PeplinskiiD· 2 shared Adeline A. Hawkins· 1 shared Afshin VarzavandiD· 1 shared Christopher S. StippiD· 1 shared Faith A. Bibeau· 1 shared Jacob L. Schillo· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Adam J. DupuyORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell lines

Rebekah M. Peplinski, Jesse D. Riordan, Jacob L. Schillo, Elizabeth C. Hannan, Silvana Pedra Nobre, Yasmin A. Lyons, Keely Ulmer, Michael Joseph Goodheart, Adam J. Dupuy

This study shows that combining MEK and PI3K-Akt inhibition enhances anti-tumor effects in LGSOC cells and may overcome resistance to MEK inhibitors.

Gynecologic Oncology · Dec 5, 2025Peer-reviewedCancer Biology

A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibition

Jesse D. Riordan, Teagan A. Nathanson, Afshin Varzavand, Adeline A. Hawkins, Rebekah M. Peplinski, Elizabeth C. Hannan, Faith A. Bibeau, Nathaniel J. Freesmeier, Madison C. Jilek, Silvia Coma, Jonathan A. Pachter, Adam J. Dupuy, Christopher S. Stipp

This study identifies FAK signaling as a critical target for overcoming Rac1-driven MAPK resistance in melanoma and shows that combining RAF/MEK and FAK inhibitors is effective.

Oncogene · Oct 18, 2025Peer-reviewedCancer Biology